Caplin Steriles, a subsidiary of Caplin Point Laboratories (NSE:CAPLIPOINT, BOM:524742) has received final approval from the US Food and Drug Administration (US FDA) for its Abbreviated New Drug Application (ANDA) for the Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution.
The drug (eye drops) is a generic therapeutic equivalent version of Abbvie Inc.'s reference-listed drug COMBIGAN, according to a Wednesday filing to the Indian stock exchanges.
Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution is used for the reduction of elevated intraocular pressure in patients with glaucoma or ocular hypertension.
As per IQVIATM estimates, Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution had sales of around $242 million for the 12 months ending December 2024 in the US.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。